about
2'-Deoxyuridine 5'-monophosphate substrate displacement in thymidylate synthase through 6-hydroxy-2H-naphtho[1,8-bc]furan-2-one derivativesBinding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors.STAT 3 as a target for cancer drug discovery.Privileged structures as leads in medicinal chemistry.Polymeric nanoparticles for the drug delivery to the central nervous system.Chapter 3 - Colloidal systems for CNS drug delivery.Ghrelin receptor modulators and their therapeutic potential.Drug delivery to the CNS and polymeric nanoparticulate carriers.Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?Interaction of nanoparticles with immunocompetent cells: nanosafety considerations.Designed multiple ligands: basic research vs clinical outcomes.Ghrelin receptor modulators: a patent review (2011 - 2014).Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors.Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.Methods for synthesis and uses of inhibitors of ghrelin O-acyltransferase inhibitors as potential therapeutic agents for obesity and diabetes.Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid.7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study.On the prodrug potential of novel aldose reductase inhibitors with diphenylmethyleneaminooxycarboxylic acid structure.Binding of 1-benzopyran-4-one derivatives to aldose reductase: a free energy perturbation study.Nitrophenyl derivatives as aldose reductase inhibitors.Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives.Heteroarylalkanoic acids with possible antiinflammatory activities, III.Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution.Synthesis of novel benzoic acid derivatives with benzothiazolyl subunit and evaluation as aldose reductase inhibitors.Magnetic and optical bistability in tetrairon(III) single molecule magnets functionalized with azobenzene groups.Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier.Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?Quantitative measurement of proton dissociation and tautomeric constants of apigeninidinGlycopeptide-Decorated Nanoparticles as Drug Carriers for CNS: Effects of Surface Coverage and Carbohydrate TypeStructural bases for the inhibition of aldose reductase by phenolic compoundsSynthesis and aldose reductase inhibitory activity of benzoyl-amino acid derivativesOxidative Modification of Aldose Reductase Induced by Copper Ion. Factors and Conditions Affecting the Process†New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agentsSynthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitorsAnti-inflammatory activity of newly synthesized 2,6-bis-(1,1-dimethylethyl)phenol derivativesAldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPHSynthesis and aldose reductase inhibitory activity of a new series of benz[h]cinnolinone derivatives
P50
Q27687326-6EA877AA-1C42-4E0E-BA91-843F2324BF6DQ29395159-BB3B342B-88F9-4C28-9953-557FB9223EC0Q33333915-95971656-DC62-4E52-8093-48159A1B4647Q36386430-60664FBE-1071-4C41-88F5-7289B22C2A6DQ37076360-F775B6A4-85C1-41E0-A3C1-2B59CA8295F4Q37714988-A4B09C17-12F0-413C-85CF-C296F6A9D99CQ37855871-D2393263-96E4-47F2-9A89-92480C666962Q37856301-8D3A3618-8ECB-469D-9485-22AC0F7847A9Q37957547-F80E5442-CDD9-488D-937E-F0B24FBEB47CQ37970755-E9E3ECD6-C1BF-444F-8F9F-63D12CA34AF7Q38017229-518822ED-F452-46AE-BCFA-2F358982A8E5Q38232345-A736FC3C-98A4-4451-9165-D0309B09A7A1Q39871204-E8300D22-0960-4807-88E6-E81E106B9502Q42165755-3551852A-3707-481B-B37B-5827833FA4ECQ42861261-E9B7A321-7302-4440-ACE8-8C7C3F929B5CQ43118634-CE0FDA5B-8CC0-4F0D-81AE-4634AD6B62D4Q43173036-28AAFF5D-9382-4A11-ACC2-028A6A96FBF0Q43774525-FD8937A3-4081-4024-807F-75759520AFD0Q43861601-A8FC5E09-BED7-4C26-BC6D-39A3269DAC1EQ43911180-EBB5EFF8-5802-4800-9B2C-67756A5AD252Q44203219-8708E163-FD6B-4808-B4ED-59E57483E79EQ44785070-C14AB620-199B-4DC3-87D0-4A9E649225C1Q45114296-43D0FFCD-2456-4A4F-91D6-718286219637Q46063843-3B618813-360F-4A04-ACEB-862032A0FB80Q46688605-8A787EC9-5ED5-46E8-B044-585F6C64E674Q46745301-6A4A23A9-FF63-4845-98F4-D83EA672B655Q48096517-53A8DC60-F1A2-46BE-91B2-66EEF00C66A6Q48528689-B4E25E5D-4A26-4B1C-9C8B-85FDE436457CQ48774664-991778E1-FA64-452E-A01F-94C7CDC53FAFQ51530606-617BB209-3666-47AB-A597-80E103CDA9B7Q56659274-E9CEDDBC-AC0C-4EE1-BDCD-3A7B5FB198D4Q59227926-8C960DF1-78E5-4246-AA17-95AAD8D9E112Q59276030-6D9C6367-5726-42B6-BBDE-4E0C6BA74706Q59276046-0BB6FE4C-37DC-496A-B208-ECAA633F7169Q61855213-B788E5FC-128F-43D0-AC41-8B48376F347BQ64071213-F1753839-98C0-491B-AEE7-00AC73231C62Q71730305-4BF66DC5-37EA-499F-BEB1-F46336FDFD50Q72915583-3B15B180-64DE-4F19-81AA-9558F6CFC4FDQ73098043-A34CAB3F-2B14-4EEE-8F39-2D5F5E3B23D0Q73333852-66A6DD4E-8B1F-41AA-A65F-4A9383855B41
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luca Costantino
@ast
Luca Costantino
@en
Luca Costantino
@es
Luca Costantino
@nl
Luca Costantino
@sl
type
label
Luca Costantino
@ast
Luca Costantino
@en
Luca Costantino
@es
Luca Costantino
@nl
Luca Costantino
@sl
prefLabel
Luca Costantino
@ast
Luca Costantino
@en
Luca Costantino
@es
Luca Costantino
@nl
Luca Costantino
@sl
P1053
D-7608-2015
P106
P1153
56238764000
P21
P31
P3829
P496
0000-0001-5334-8084